Does Rallies show 13F holders for TGTX?

Yes. Rallies tracks hedge fund and 13F ownership data for TGTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TGTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TGTX. It does not provide personalized investment advice.

TGTX (TG Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

TG Therapeutics, Inc. (TGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, TGTX trades at $39.59 with a market cap of $6.04B and a P/E ratio of 12.32. TGTX moved +0.84% today. Year to date, TGTX is +32.98%; over the trailing twelve months it is +12.09%. Its 52-week range spans $21.16 to $46.48. Analyst consensus is neutral with an average price target of $44.25. Rallies surfaces TGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TGTX stock?

Hedge funds tracked by Rallies that own TGTX include Bridgewater Associates, Duquesne Family, Orbimed Advisors, Panagora Asset, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TG Therapeutics, Inc..

TGTX Key Metrics

Key financial metrics for TGTX
Metric	Value
Price	$39.59
Market Cap	$6.04B
P/E Ratio	12.32
EPS	$3.22
Dividend Yield	0.00%
52-Week High	$46.48
52-Week Low	$21.16
Volume	4.81K
Avg Volume	0
Revenue (TTM)	$700.35M
Net Income	$461.90M
Gross Margin	83.05%

Top Hedge Funds Holding TGTX

Bridgewater Associates holds 311.42K shares of TGTX, changed -33.72% as of Mar 31, 2026.
Duquesne Family holds 280.00K shares of TGTX, changed +0.00% as of Mar 31, 2024.
Orbimed Advisors holds 133.20K shares of TGTX, changed +0.00% as of Jun 30, 2024.
Panagora Asset holds 30.04K shares of TGTX, changed -81.30% as of Mar 31, 2025.
Polen Capital holds 14.77K shares of TGTX, changed +0.00% as of Jun 30, 2025.

Latest TGTX News

TG Therapeutics Poised for 6.6% Gain as Implied Volatility Hits 6th Percentile — May 11, 2026
TG Therapeutics jumps as Q1 revenue hits ~$205M and 2026 guidance rises — May 6, 2026
TG Therapeutics rises as traders position for May 6 Q1 update, BRIUMVI focus — May 4, 2026
TG Therapeutics drops as investors de-risk ahead of May 4 earnings after April rally — Apr 29, 2026
TG Therapeutics slips 3% as traders de-risk into May 4 earnings amid oil-driven risk-off — Apr 27, 2026

Recent TGTX Insider Trades

Echelard Yann sold 5.00K (~$162.85K) on Nov 24, 2025.
Lonial Sagar sold 20.85K (~$672.27K) on Sep 11, 2025.
Echelard Yann sold 10.00K (~$369.40K) on Jun 13, 2025.

TGTX Analyst Consensus

4 analysts cover TGTX: 0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.25.

Common questions about TGTX

Who owns TGTX stock?: Hedge funds tracked by Rallies that own TGTX include Bridgewater Associates, Duquesne Family, Orbimed Advisors, Panagora Asset, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for TG Therapeutics, Inc..
Does Rallies show 13F holders for TGTX?: Yes. Rallies tracks hedge fund and 13F ownership data for TGTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TGTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TGTX. It does not provide personalized investment advice.